MedWatch

Genmab CEO lands USD 6.8m salary in 2021

After three years with results in line with analysts’ expectations, the CEO of Danish biotech company Genmab has received a raise, bringing his 2021 wages to DKK 44.3m (USD 6.8m).

Photo: Mik Eskestad/ERH

CEO at Genmab Jan van de Winkel’s wallet has become thicker again this year, following a 2021 in which the Danish biotech company largely lived up to expectations with a revenue of DKK 8.5bn (USD 1.3bn) and an operating profit (EBIT) of DKK 3bn (USD 461m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs